The tubal epigenome - An emerging target for ovarian cancer

Area of Science:

• Gynecologic Oncology
• Epigenetics
• Molecular Pathology

Background:

• Ovarian cancer, particularly high-grade serous ovarian carcinoma (HGSC), is a leading cause of cancer mortality in the United States.
• Mortality is driven by difficulties in early detection and the development of therapeutic resistance.
• Emerging evidence suggests HGSC originates from aberrant fallopian tube epithelial (FTE) cells.

Purpose of the Study:

• To provide a comprehensive overview of early epigenetic reprogramming in FTE cells preceding HGSC.
• To examine how these epigenetic alterations influence intrinsic and extrinsic tumor properties.
• To explore the potential of targeting the epigenome for HGSC prevention and treatment.

Main Methods:

• Literature review and synthesis of current research on epigenetic alterations in FTE cells.
• Analysis of studies investigating the link between epigenetic changes and HGSC pathogenesis.
• Exploration of therapeutic strategies targeting epigenetic modifications.

Main Results:

• Epigenetic reprogramming in FTE cells is a critical early event in HGSC development.
• These epigenetic alterations impact cellular behavior, promoting migration and colonization.
• The epigenome presents a promising target for novel therapeutic interventions and early detection biomarkers.

Conclusions:

• Understanding early epigenetic changes in FTE cells is crucial for deciphering HGSC origins.
• Targeting epigenetic modifications in FTE cells holds significant potential for preventing and treating HGSC.
• Epigenetic strategies may overcome current challenges in ovarian cancer management.